MX2024001607A - Compuestos de complejos de hierro para uso subcutáneo en la terapia de la ferropenia en animales de compañía. - Google Patents
Compuestos de complejos de hierro para uso subcutáneo en la terapia de la ferropenia en animales de compañía.Info
- Publication number
- MX2024001607A MX2024001607A MX2024001607A MX2024001607A MX2024001607A MX 2024001607 A MX2024001607 A MX 2024001607A MX 2024001607 A MX2024001607 A MX 2024001607A MX 2024001607 A MX2024001607 A MX 2024001607A MX 2024001607 A MX2024001607 A MX 2024001607A
- Authority
- MX
- Mexico
- Prior art keywords
- iron
- therapy
- complex compounds
- iron deficiency
- companion animals
- Prior art date
Links
- 206010022971 Iron Deficiencies Diseases 0.000 title abstract 3
- -1 Iron complex compounds Chemical class 0.000 title abstract 3
- 238000007920 subcutaneous administration Methods 0.000 title abstract 3
- 238000002560 therapeutic procedure Methods 0.000 title abstract 3
- 241001465754 Metazoa Species 0.000 title abstract 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 abstract 6
- 229910052742 iron Inorganic materials 0.000 abstract 3
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 239000003937 drug carrier Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/721—Dextrans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a compuestos de complejos de hierro para uso subcutáneo en un método de terapia, por ejemplo, para la ferropenia, particularmente la anemia ferropénica, en un animal de compañía y a composiciones farmacéuticas para administración subcutánea, que comprenden un compuesto de complejo de hierro y un portador farmacéuticamente aceptable. La presente invención se refiere más particularmente, aunque no exclusivamente, a complejos de hierro octasacárido, a composiciones farmacéuticas que comprenden un complejo de hierro octasacárido y a los complejos de hierro octasacárido para su uso en un método de terapia de la ferropenia, particularmente de la anemia ferropénica, en un sujeto humano o no humano.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21189392 | 2021-08-03 | ||
| PCT/EP2022/071875 WO2023012242A1 (en) | 2021-08-03 | 2022-08-03 | Iron complex compounds for subcutaneous use in therapy of iron deficiency in companion animals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024001607A true MX2024001607A (es) | 2024-02-27 |
Family
ID=77206986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024001607A MX2024001607A (es) | 2021-08-03 | 2022-08-03 | Compuestos de complejos de hierro para uso subcutáneo en la terapia de la ferropenia en animales de compañía. |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4380581A1 (es) |
| JP (1) | JP2024529536A (es) |
| KR (1) | KR20240041957A (es) |
| CN (1) | CN118019542A (es) |
| AU (1) | AU2022323733A1 (es) |
| BR (1) | BR112024002150A2 (es) |
| CA (1) | CA3226771A1 (es) |
| MX (1) | MX2024001607A (es) |
| WO (1) | WO2023012242A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026017897A1 (en) | 2024-07-18 | 2026-01-22 | Malian Biologicals Gmbh | Iron supplementation in affective disorders and/or post-traumatic stress disorder (ptsd) and/or serotonin-dependent diseases |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3639588A (en) | 1966-10-22 | 1972-02-01 | Fisons Pharmaceuticals Ltd | Pharmaceutical compositions containing ferric hydroxide complexed with dextran or dextrin heptonic acids |
| US3906077A (en) | 1974-02-15 | 1975-09-16 | Kerr Mc Gee Chem Corp | Purification of ferric chloride |
| US4056386A (en) | 1977-04-19 | 1977-11-01 | The United States Of America As Represented By The Secretary Of The Navy | Method for decomposing iron pentacarbonyl |
| CA2318823A1 (en) | 1998-02-25 | 1999-09-02 | Satish C. Wadhawan | Solvent extraction of ferric chloride |
| DK172860B1 (da) | 1998-03-25 | 1999-08-16 | Pharmacosmos Holding As | Jerndextranforbindelse til anvendelse som komponent i et terapeutisk middel til forebyggelse af eller behandling af jernman |
| CN1309741C (zh) * | 2002-04-09 | 2007-04-11 | 法玛科思莫斯控股有限公司 | 用于治疗缺铁性贫血的铁糊精化合物 |
| RU2338516C2 (ru) * | 2006-11-08 | 2008-11-20 | Федеральное государственное образовательное учреждение высшего профессионального образования "Кубанский государственный аграрный университет" | Железосодержащее средство для профилактики и лечения анемии у животных |
| AU2008212653B2 (en) | 2007-02-06 | 2012-05-24 | United Kingdom Research And Innovation | Ligand modified poly oxo-hydroxy metal ion materials, their uses and processes for their preparation |
| EP2285423B1 (en) | 2008-04-22 | 2020-03-18 | MegaPro Biomedical Co., Ltd. | Biocompatible polymer and magnetic nanoparticle with biocompatibility |
| HUE030866T2 (en) | 2009-03-25 | 2017-06-28 | Pharmacosmos Holding As | A stable iron oligosaccharide compound |
| EP2537866A1 (en) | 2011-06-21 | 2012-12-26 | Serumwerk Bernburg AG | Hydroxyethyl starch derivatives, method for manufacturing the same and therapeutical uses thereof |
| CN116898874A (zh) * | 2015-06-22 | 2023-10-20 | 法码科思莫斯控股有限公司 | 用于治疗胎儿或婴儿铁缺乏的铁碳水化合物复合物 |
| WO2018226747A1 (en) | 2017-06-06 | 2018-12-13 | Kindred Biosciences, Inc. | Erythropoietin and analogs for veterinary use |
| SG11202001594TA (en) | 2017-09-11 | 2020-03-30 | Pharmacosmos Holding As | Iron complex compounds for therapeutic use |
| WO2020144667A1 (en) * | 2019-01-10 | 2020-07-16 | Pharmacosmos Holding A/S | Treating iron deficiency in subjects at risk of cardiovascular adverse events and iron for the management of atrial fibrillation |
| EA202191858A1 (ru) * | 2019-06-12 | 2021-11-12 | Фармакосмос Холдинг А/С | Лечение дефицита железа у субъектов с риском нежелательных явлений со стороны сердечно-сосудистой системы и железо для лечения фибрилляции предсердий |
-
2022
- 2022-08-03 CN CN202280064943.3A patent/CN118019542A/zh active Pending
- 2022-08-03 JP JP2024506697A patent/JP2024529536A/ja active Pending
- 2022-08-03 MX MX2024001607A patent/MX2024001607A/es unknown
- 2022-08-03 CA CA3226771A patent/CA3226771A1/en active Pending
- 2022-08-03 BR BR112024002150A patent/BR112024002150A2/pt not_active Application Discontinuation
- 2022-08-03 AU AU2022323733A patent/AU2022323733A1/en active Pending
- 2022-08-03 KR KR1020247005769A patent/KR20240041957A/ko active Pending
- 2022-08-03 EP EP22760750.4A patent/EP4380581A1/en active Pending
- 2022-08-03 WO PCT/EP2022/071875 patent/WO2023012242A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024529536A (ja) | 2024-08-06 |
| CA3226771A1 (en) | 2023-02-09 |
| WO2023012242A1 (en) | 2023-02-09 |
| AU2022323733A1 (en) | 2024-02-29 |
| CN118019542A (zh) | 2024-05-10 |
| EP4380581A1 (en) | 2024-06-12 |
| BR112024002150A2 (pt) | 2024-04-30 |
| KR20240041957A (ko) | 2024-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017502079A1 (en) | Treatment of beta-thalassemia using actrii ligand traps | |
| MXPA05006685A (es) | Antibioticos que contienen complejos de acido borinico y metodos de uso. | |
| TW200612939A (en) | Antibiotics containing borinic acid complexes and methods of use | |
| CA2531862A1 (en) | Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability | |
| TNSN07341A1 (en) | Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer | |
| SA523450286B1 (ar) | مركب 4-أمينو كوينازولين | |
| WO2018045348A3 (en) | ANTICANCER POLY THERAPY WITH PENTAAZA MACROCYCLIC CYCLE COMPLEX AND ASCORBATE COMPOUND | |
| MX2024011249A (es) | Dosificacion no lineal de mirdametinib. | |
| IL151628A0 (en) | Combination therapies with vascular damaging activity | |
| MX2022011372A (es) | Composiciones de zinc-y-pga y metodos para tratar el cancer. | |
| TN2022000113A1 (en) | Dosing regimen for anti-dll3 agents | |
| MX2007003506A (es) | Terapia de combinacion de cancer que comprende azd2171 e imatinib. | |
| MX2023011203A (es) | Derivado de cumarina para terapia o profilaxis de un trastorno proliferativo celular. | |
| MX2007003505A (es) | Combinacion que comprende zd6474 e imatinib. | |
| MX2023013225A (es) | Inhibidores de la cinasa 4 similar a polo. | |
| MX2024001607A (es) | Compuestos de complejos de hierro para uso subcutáneo en la terapia de la ferropenia en animales de compañía. | |
| MX2015015434A (es) | Corroles dirigidas para toxicidad tumoral y rm. | |
| MX2020007817A (es) | Prevención y tratamiento del trastorno del sueño. | |
| PT1765360E (pt) | Utilizações antivirais de complexos de ácido borínico | |
| MX2019010651A (es) | Aparato y métodos para administración de un compuesto nauseogénico desde un dispositivo de administración de fármacos. | |
| MX2022011171A (es) | Compuestos con actividad inmunomodulatoria y usos terapeuticos de estos. | |
| IN2014DN04596A (es) | ||
| CA2531620A1 (en) | Cancer combination therapy comprising azd2171 and zd1839 | |
| MX2022000308A (es) | Formulacion de nanoparticulas de inhibidor de bcl-2. | |
| TW200610530A (en) | Anti-parasitic uses of borinic acid complexes |